Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe

We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011–2014 but increased during 2015–2018 in all age groups. From the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanquet, Germaine, Krizova, Pavla, Dalby, Tina, Ladhani, Shamez N., Nuorti, J. Pekka, Danis, Kostas, Mereckiene, Jolita, Knol, Mirjam J., Winje, Brita A., Ciruela, Pilar, de Miguel, Sara, Portillo, Maria Eugenia, MacDonald, Laura, Morfeldt, Eva, Kozakova, Jana, Valentiner-Branth, Palle, Fry, Norman K., Rinta-Kokko, Hanna, Varon, Emmanuelle, Corcoran, Mary, van der Ende, Arie, Vestrheim, Didrik F., Munoz-Almagro, Carmen, Sanz, Juan-Carlos, Castilla, Jesus, Smith, Andrew, Henriques-Normark, Birgitta, Colzani, Edoardo, Pastore-Celentano, Lucia, Savulescu, Camelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714201/
https://www.ncbi.nlm.nih.gov/pubmed/34932457
http://dx.doi.org/10.3201/eid2801.210734
Descripción
Sumario:We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011–2014 but increased during 2015–2018 in all age groups. From the 7-valent PCV period to 2018, IPD incidence declined by 42% in children <5 years of age, 32% in persons 5–64 years of age, and 7% in persons >65 years of age; non-PCV13 serotype incidence increased by 111%, 63%, and 84%, respectively, for these groups. Trends were similar in countries using PCV13 or PCV10, despite different serotype distribution. In 2018, serotypes in the 15-valent and 20-valent PCVs represented one third of cases in children <5 years of age and two thirds of cases in persons >65 years of age. Non-PCV13 serotype increases reduced the overall effect of childhood PCV10/PCV13 programs on IPD. New vaccines providing broader serotype protection are needed.

Ejemplares similares